Incyte Corporation (0J9P.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
As of 02:39PM BST. Market open.
| Previous close | 51.99 |
| Open | 51.62 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 51.62 - 51.62 |
| 52-week range | 50.81 - 75.42 |
| Volume | |
| Avg. volume | 2,831 |
| Market cap | 112.533M |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | 0.12 |
| EPS (TTM) | 4.20 |
| Earnings date | 30 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksIncyte (INCY) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksIncyte (INCY) to Report Q1 Earnings: What's in the Cards?
Incyte's (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
Business WireIncyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
WILMINGTON, Del. & SAN DIEGO, April 23, 2024--Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
© 2024 Yahoo. All rights reserved.